![陳寶安[全國知名血液病與腫瘤學專家]](/img/5/1f4/nBnauM3X0EzMygTN4YTN0ETN1UTM1QDN5MjM5ADMwAjMwUzL2UzL4YzLt92YucmbvRWdo5Cd0FmLxE2LvoDc0RHa.jpg "陳寶安[全國知名血液病與腫瘤學專家]")
個人履歷
現任東南大學附屬中大醫院血液科學科帶頭人、骨髓增生異常綜合徵研究所所長、腫瘤學系主任。兼任中國抗癌協會臨床腫瘤學協作專業委員會執行委員、江蘇省抗癌協會理事、中華醫學會江蘇省血液學會副主任委員、中華醫學會南京血液學會前主任委員。 1979年畢業於南京鐵道醫學院醫療系（今東南大學醫學院），畢業後先後在南京鐵道醫學院完成碩士，上海醫科大學（今復旦大學上海醫學院）完成博士學位，在德國烏爾姆大學血液腫瘤科完成博士後研究工作，美國MD Aderson Cancer Center、加州大學伯克利分校、德國海德堡大學等多所世界著名大學高級訪問學者。
研究方向
1.腫瘤耐藥方面的研究：白血病治療失敗的主要原因之一為多藥耐藥，在國家自然科學基金資助下，研究發現漢防己甲素是一種非選擇性鈣離子通道阻滯劑，它能提高化療藥物對白血病細胞的抑制率，且對正常的骨髓細胞無抑制作用。心肌毒副作用低，實驗用量臨床可以接受；他莫西芬可通過改善膜結構，竟爭性抑制膜糖蛋白對化療藥物的轉運。二者單獨套用均能逆轉多藥耐藥。經專家評定，此方面研究已達到國際先進水平。
2.基因晶片技術的研究：已完成了檢測腫瘤微轉移的基因晶片的研究，並獲得了國家智慧財產權及發明專利；並進行了蛋白質晶片的研究，《套用蛋白質晶片檢測多藥耐藥蛋白表達水平》於中華腫瘤雜誌2005年發表。目前由江蘇省衛生廳資助的重點項目“微轉移基因晶片研製及在消化道惡性腫瘤中的套用研究”正在進行中。
3.阻斷腫瘤新生血管的物理原理及生物效應：針對腫瘤血管生成的治療措施可成為一個新穎抗癌途徑。目前此方面的研究主要集中在對腫瘤血管生成因子，和抗內皮細胞增殖和遷移的方面。通過前期研究，發現通過超聲空化及空化核的增強效應，直接損傷腫瘤新生血管，並已完成了低功率超聲輻射二氧化碳微泡劑致使腫瘤血管拴塞的實驗研究，。將進一步對動物移植瘤做進一步的研究，並準備進行臨床研究，以期建立無創誘導致腫瘤新生血管內皮細胞損傷及阻斷腫瘤血液供應的新方法。
4.造血幹細胞移植：近幾年開展了非清髓造血幹細胞移植36例，療效滿意，治療相關毒副反應小，經濟費用較低，使白血病患者擺脫了病痛，目前處於國內領先水平，在全國範圍內產生了深遠影響。
獲獎記錄
1. 2007年“白血病的耐藥逆轉研究”江蘇省科技進步二等獎
2.2006年“消化道惡性腫瘤患者外周血微轉移檢測及微轉移基因晶片研製及其套用”江蘇省科學技術進步獎三等獎
3. 2006年“中西藥結合增加血液系統腫瘤化療敏感性的基礎與臨床研究”中國中西醫結合學會科技獎三等獎
4.2009 年“多種方法逆轉白血病多藥耐藥的研究及套用”獲教育部科技進步二等獎。
5. 2011 年“基於納米生物技術的腫瘤耐藥識別與逆轉的研究”獲教育部科技進步二等獎。
先後獲教育部科技進步二等獎、江蘇省科技進步二等獎。國家級課題5項，省部級二等獎3項。
獲得專利
1.王雪梅，張仁雲，呂剛，吳春惠，李景源，高峰，程堅，陳寶安，付德剛，李小毛，
關之群. 治療白血病的靶向磁性納米藥物及製備方法. 專利號：ZL 2005 1 0040657.1。
2.王雪梅，吳春惠，宋敏，李景源，張仁雲，吳德洪，燕紅，顧忠澤，陳寶安. 有機金
屬碳硼烷靶向納米製劑的製備方法及製成的靶向製劑. 專利號： ZL 2006 1 0096423.3。
課題項目
1. 國家自然科學基金面上項目：漢防已甲素和角羅西芬逆轉白血病細胞多藥耐藥的機理研究（編號：39970832，研究年限：2000.11－2002.12）已結題
2. 南京市重大課題：非清髓造血幹細胞移植治療白血病（編號：YQ0008，研究年限：2001－2004）已結題
3. 江蘇省衛生廳科技發展基金：生物療法在慢粒ASCT體外淨化作用（編號：H200344，研究年限：2003－2005）已結題
4. 東南大學中大醫院重大課題：非清髓造血幹細胞移植治療血液病（編號：2003YJ02，研究年限：2003－2005）已結題
5. 高等學校博士學科點專項科研基金：共聚合漢防己甲素和化療藥物的磁性納米四氧化三鐵顆粒在逆轉惡性血液病多藥耐藥中的機理研究（編號：20070286042，研究年限：2008－2010）已結題
6. 國家自然基金面上項目：共聚合漢防己甲素和化療藥物的磁性納米四氧化三鐵顆粒在逆轉惡性血液病多藥耐藥中的機理研究（編號：30740062，研究年限：2008－2009）已結題7. 國家自然基金面上項目：磁性納米四氧化三鐵顆粒共聚合柔紅黴素和5－溴漢防己甲素逆轉惡性血液病多藥耐藥的機理研究（編號：30872970，研究年限：2009－2011）已結題8. 國家高技術研究發展計畫（863計畫）子課題：急性白血病的治療（研究年限：2009－2011）已結題
9. 國家高技術研究發展計畫（863計畫）子課題：超靈敏納米多孔生物感測器件的研究與開發（編號：32007AA022007，研究年限：2009－2011）已結題
10. 國家重點基礎研究發展計畫（973計畫）子課題：基於仿生分子識別的感測與成像方法研究及其系統設計（編號：2010CB732404，研究年限：2009-2015）在研
11. 國家科技支撐計畫課題（十一五）子課題：骨髓增生異常綜合徵的規範化診斷與治療策略研究（編號：2008BAI61B02，研究年限：2008－2010）已結題
12. 國家自然基金面上項目：化療藥和中藥與轉鐵蛋白納米載體的設計及逆轉白血病耐藥的機制研究（編號：81170492，研究年限：2012－2015）在研
13. 國家高技術研究發展計畫（863計畫）子課題：針對生物標誌物檢測的低成本檢測系統的研製（編號：2012AA022703，研究年限：2012－2016）在研
14. 國家自然基金面上項目：血小板靶向載藥系統的研製及其抗白血病效應的研究（編號：81370673，研究年限：2014－2017）在研
15. 江蘇省科技廳醫學重點項目：江蘇省復發和難治性白血病的規範化治療（編號：BL2014078，研究年限：2014－2017）在研
發表論文
1.CaiX, Cai X, Wang C, Chen B A*, Hua W, Shen F et al. Antitumor efficacy of DMSA modified Fe3O4 magneticnanoparticles combined with arsenic trioxide and adriamycin in Raji cells. J Biomed Nanotech2014; 10(2) : 251-261.
2.ChangH, Wang X, Shiu KK, Zhu Y, Wang J, Li Q, Chen BA* et al. Layer-by-layer assembly of graphene, Au andpoly(toluidine blue O) films sensor for evaluation of oxidative stress of tumorcells elicited by hydrogen peroxide. Biosensors& Bioelectronics 2013; 41: 789-794.
3.ChengJ, Cheng L, Chen B A*, Xia G, Gao C, Song H et al. Effect of magnetic nanoparticles of Fe3O4 and wogonin onthe reversal of multidrug resistance in K562/A02 cell line. Int J Nanomedicine 2012; 7: 2843-2852.
4.FangL, Chen B A,Liu S, Wang R, Hu S, Xia G, Chen BA* et al.Synergistic effect of a combination of nanoparticulate Fe3O4 and gambogic acidon phosphatidylinositol 3-kinase/Akt/Bad pathway of LOVO cells. Int JNanomedicine 2012; 7: 4109-4118.
5.JiangN, Zhu X, Zhang H, Wang X, Zhou X, Gu J, Chen BA * et al. The relationship between methylenetetrahydrofolatereductase polymorphism and hematological malignancy. Clin Lab2014; 60(5) : 767-774.
6.JinN, Malcherek G, Mani J, Zurleit R, Schmitt A, Chen B A et al. Suppression of cytomegalovirus-specific CD8(+)T cells by everolimus. Leuk Lymphoma 2014; 55(5) : 1144-1150.
7.LiK, Chen B A*,Xu L, Feng J, Xia G, Cheng J et al.Reversal of multidrug resistance by cisplatin-loaded magnetic Fe3O4nanoparticles in A549/DDP lung cancer cells in vitro and in vivo. Int J Nanomedicine 2013; 8: 1867-1877.
8.LiangG, Li J, Sun B, Li S, Lu L, Wang Y, Chen BA* et al. Deep sequencing reveals complex mechanisms ofmicroRNA deregulation in colorectal cancer. Int J Oncology 2014; 45(2) : 603-610.
9.LuX, Zhu A, Cai X, Jia Z, Han W, Ma L, Chen BA* et al. Role of NKG2D in cytokine-induced killer cellsagainst multiple myeloma cells. CancerBio Therapy 2012; 13(8) : 623-629.
10.MouY, Hou Y, Chen B A*, Hua Z, Zhang Y, Xie H et al. In vivo migration of dendritic cells labeled with syntheticsuperparamagnetic iron oxide. Int J Nanomedicine 2011; 6: 2633-2640.
11.RenY, Zhang H, Chen B A*, Cheng J, Cai X, Liu R et al. Multifunctional magnetic Fe3O4 nanoparticles combined withchemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine 2012; 7: 2261-2269.
12.SongG, Gu L, Li J, Tang Z, Liu H, Chen B A* et al. Serum microRNAexpression profiling predict response to R-CHOP treatment in diffuse large Bcell lymphoma patients. Ann Hematol 2014.e-pub ahead of print 2014/05/27
13.WangC, Cai X, Chen B A*, He Z, Chen Z, Cen J et al. Up-regulation of tissue inhibitor of metalloproteinase-2promotes SHI-1 cell invasion in nude mice. Leuk Lymphoma 2013; 54(12) : 2707-2711.
14.WangC, Zhang H, Chen Y, Shi F, Chen B A*. Gambogic acid-loaded magnetic Fe(3)O(4)nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migrationby inactivating transcription factor ETS1. Int J Nanomedicine 2012; 7: 781-787.
15.Wang F, Zhang W, Guo L, Bao W,Jin N, Liu R, Chen BA* et al. Gambogic acid suppresses hypoxia-inducedhypoxia-inducible factor-1alpha /vascular endothelial growth factor expressionvia inhibiting phosphatidylinositol 3-kinase/Akt/mammalian target protein ofrapamycin pathway in multiple myeloma cells. Cancer Sci2014. e-pub ahead of print 2014/06/04.
16.WangL, Zhang H, Chen B A*, Xia G, Wang S, Cheng J et al. Effect of magnetic nanoparticleson apoptosis and cell cycle induced by wogonin in Raji cells. Int J Nanomedicine 2012; 7: 789-798.
17.WangX, Wang X, Gao S, Zheng Y, Tang M, ChenB A*. A solid-state electrochemiluminescencesensing platform for detection of catechol based on novel luminescent compositenanofibers. Talanta 2013; 107: 127-132.
18.WenJ, Jiang S, Chen Z, Zhao W, Yi Y, Yang R, Chen BA * et al. Apoptosis selectively induced in BEL-7402 cells byfolic acid-modified magnetic nanoparticles combined with 100 Hz magnetic field.Int J Nanomedicine 2014; 9: 2043-2050.
19.XuP, Chen B A*,Feng J, Cheng L, Xia G, Li Y et al.Polymorphisms in XPC provide prognostic information in acute myeloid leukemia. Int J Hematology 2012; 96(4) : 450-460.
20.XuP, Li J, Chen B A*, Wang X, Cai X, Jiang H et al. The real-time neurotoxicityanalysis of Fe3O4 nanoparticles combined with daunorubicin for rat brain invivo. J Biomed Nanotechnology 2012; 8(3) : 417-423.
21.XuP, Li J, Shi L, Selke M, Chen B A*, Wang X. Synergetic effect of functionalcadmium-tellurium quantum dots conjugated with gambogic acid for HepG2cell-labeling and proliferation inhibition. Int J Nanomedicine 2013; 8: 3729-3736.
22.XuY, Wang Y, Li XM, Huang Q, Chen W, Liu R, Chen BA* et al. Study on the release of fenofibrate nanosuspension invitro and its correlation with in situ intestinal and in vivo absorptionkinetics in rats. Drug Dev Indus Pharmacy2014; 40(7) : 972-979.
23.YangZ, Chen B A*,Pei X, Shangguan F. Multiplex analysis of tumor multidrug-resistance genesexpression with photonic suspension array. TheAnalyst 2012; 137(14) : 3343-3348.
24.ZhangH, Wang C, Chen B A*, Wang X. Daunorubicin-TiO2 nanocompositesas a "smart" pH-responsive drug delivery system. Int J Nanomedicine 2012; 7: 235-242.
25.ZhongY, Wu J, Chen B A*, Ma R, Cao H, Wang Z et al. Investigation and analysis of single nucleotidepolymorphisms in Janus kinase/signal transducer and activator of transcriptiongenes with leukemia. Leuk Lymphoma 2012; 53(6) : 1216-1221.
26. Zhang HJ, Chen BA*,Jiang H, Wang CL, Wang HP, Wang XM. A strategy for ZnO nanorod mediatedmulti-mode cancer treatment. Biomaterials. 2011; 32(7):1906-14.
27. Chen BA*, Wu WW, WangXM. Magnetic Iron Oxide Nanoparticles for Tumor-targeted Therapy. Curr CancerDrug Targets 2011; 11(2):184-9.
28. Zhang HJ, Jiang H, Sun FF, Wang HP, Zhao J, Chen BA*, Wang XM. Rapid diagnosis of multidrug resistance in cancerby electrochemical sensor based on carbon nanotubes-drug supramolecularnanocomposites. Biosens Bioelectron. 2011; 26(7):3361-6.
29. Song M, Zhang RR, Dai YY, Gao F, Chi H, Lv G, Chen BA, * Wang XM. The in vitro inhibitionof multidrug resistance by combined nanoparticulate titanium dioxide and UV irradition.Biomaterials. 2006; 27(23):4230-8.
30. Chen BA*, Yin L, ChengJ, Ding JH, Gao C, Sun YY, Zhao G, Wang J, Bao W, Xia GH, Gao F, Wang XM.Effect of D, L-threo-1-phenyl-2-decanoylamino-3-morpholino-1 -propanol andtetrandrine on the reversion of multidrug resistance in K562/A02 cells.Hematology. 2011; 16(1):24-30.
31. Wu WW, Chen BA*, ChengJ, Wang J, Xu WL, Liu LJ, Xia GH, Wei H, Wang XM, Yang M, Yang L, Zhang Y, XuC, Li J. Biocompatibility of Fe3O4/DNR magnetic nanoparticles inthe treatmentof hematologic malignancies. Int J Nanomedicine. 2010; 5:1079-84.
32. Wang J, Chen Y, Chen BA*,Ding JH, Xia GH, Gao C, Cheng J, Jin N, Zhou Y, Li XM, Tang M, Wang XM.Pharmacokinetic parameters and tissue distribution of magnetic Fe(3)O(4) nanoparticlesin mice. Int J Nanomedicine. 2010; 5:861-6.
33. Chen BA*, Mao P, ChengJ, Gao F, Xia GH, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, Chen W, Chen N, LiuLJ, Li XM, Wang XM. Reversal of multidrug resistance by magnetic Fe3O4nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector inleukemia cells. Int J Nanomedicine. 2010; 5:437-4.
34. Chen BA*, Jin N, WangJ, Ding JH, Gao C, Cheng J, Xia GH, Gao F, Zhou Y, Chen Y, Zhou G, Li XM, ZhangY, Tang M, Wang XM. The effect of magnetic nanoparticles of Fe(3)O(4) on immunefunction in normal ICR mice. Int J Nanomedicine. 2010; 5:593-9.
35. Zhang HJ, Jiang H, Wang XM, Chen BA *. Reversion of multidrugresistance in tumor by biocompatible nanomaterials. Mini Rev Med Chem. 2010;10(8):737-45.
36. Zhong YJ, Chen BA*,Feng JF, Cheng L, Li Y, Qian J, Ding JH, Gao F, Xia GH, Chen N, Lu Z. Theassociations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomesin patients with acute myeloid leukemia. Leuk Lymphoma. 2010; 51(6):1115-20.
37. Zhu XL, Zhang HJ, Lin Y, Chen P, Min J, Wang Z, Xiao W, Chen BA*. Mechanisms of gambogicacid-induced apoptosis in non-small cell lung cancer cells in relation to transferrinreceptors. J Chemother. 2009; 21(6):666-72.
38. Pei XP, Chen BA*, LiL, Gao F, Jiang Z. Multiplex tumor marker detection with new chemiluminescentimmunoassay based on silica colloidal crystal beads. Analyst. 2010; 135(1):177-81.
39. Chen BA*, Liang YQ, WuWW, Cheng J, Xia GH, Gao F, Ding JH, Gao C, Shao Z, Li G, Chen W, Xu WL, SunXC, Liu LJ, Li XM, Wang XM. Synergistic effect of magnetic nanoparticles ofFe(3)O(4) with gambogic acid on apoptosis of K562 leukemia cells. Int J Nanomedicine.2009; 4:251-9.
40. Cheng J, Wu WW, Chen BA*,Gao F, Xu WL, Gao C, Ding JH, Sun YY, Song HH, Bao W, Sun XC, Xu C, Chen W,Chen N, Liu LJ, Xia GH, Li XM, Wang XM. Effect of magnetic nanoparticles ofFe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02leukemic cells. Int J Nanomedicine. 2009; 4:209-16.
41. Pei XP, Zhao Y, Zhao X, Xu H, Chen BA*, Gu ZZ. Multiplex chemiluminescent immunoassay based onsilica colloidal crystal beads. J N N. 2009; 9(11):6320-5.
42. Sun N, Sun XC, Chen BA*,Cheng H, Feng JF, Cheng L, Lu ZH. MRP2 and GSTP1 polymorphisms and chemotherapyresponse in advanced non-small cell lung cancer. Cancer Chemoth Pharm. 2010;65(3):437-46.
43. Li Y, Deng Z, Xuan H, Zhu J, Ding B, Liu X, Chen BA*. Prolonged chronic phase in chronic myelogenous leukemiaafter homoharringtonine therapy. Chin Med J (Engl). 2009;122(12):1413-7.
44. Jiang Z, Chen BA*, XiaGH, Wu Q, Zhang Y, Hong T, Zhang W, Cheng J, Gao F, Liu LJ, Li XM, Wang XM. Thereversal effect of magnetic Fe3O4 nanoparticles loaded with cisplatin onSKOV3/DDP ovarian carcinoma cells. Int J Nanomedicine. 2009; 4:107-14.
45. Chen BA*, Cheng J, WuYN, Gao F, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, Sun XC, Cheng H, Li G, ChenW, Chen N, Liu LJ, Li XM, Wang XM. Reversal of multidrug resistance by magneticFe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine inxenograft nude-mice. Int J Nanomedicine. 2009; 4:73-8.
46. Chen BA*, Cheng J,Shen MF, Gao F, Xu WL, Shen HL, Ding JH, Gao C, Sun Q, Sun XC, Cheng H, Li G,Chen W, Chen N, Liu LJ, Li XM, Wang XM. Magnetic nanoparticle of Fe3O4 and5-bromotetrandrin interact synergistically to induce apoptosis by daunorubicin inleukemia cells. Int J Nanomedicine. 2009; 4:65-71.
47. Chen BA*, Dai YY, WangXM, Zhang R, Xu WL, Shen HL, Gao F, Sun Q, Deng X, Ding JH, Gao C, Sun Y, ChengJ, Wang J, Zhao G, Chen N. Synergistic effect of the combination of nanoparticulateFe3O4 and Au with daunomycin on K562/A02 cells. Int J Nanomedicine. 2008;3(3):343-50.
48. Chen BA*, Sun Q, WangXM, Gao F, Dai YY, Yin Y, Ding JH, Gao C, Cheng J, Li JY, Sun XC, Chen N, XuWL, Shen HL, Liu D. Reversal in multidrug resistance by magnetic nanoparticleof Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells. IntJ Nanomedicine. 2008; 3(2):277-86.
個人貢獻
主編《惡性腫瘤多藥耐藥的逆轉》一部 ，參編著作多部，主持國家自然科學基金5項、參與“973”、“863” 、科技支撐等多項研究項目。累計發表學術論文400餘篇，其中SCI收錄近百篇，主（參）編著作3部。
